{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:11:16Z","timestamp":1794892276104,"version":"4.9.1"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","funder":[{"DOI":"10.13039\/501100004497","name":"Onderzoeksraad, KU Leuven","doi-asserted-by":"crossref","award":["KGG-E1099STG\/21\/005"],"award-info":[{"award-number":["KGG-E1099STG\/21\/005"]}],"id":[{"id":"10.13039\/501100004497","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010648","name":"Universitaire Ziekenhuizen Leuven, KU Leuven","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010648","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>In adult patients with sepsis or septic shock admitted to the emergency department, a single intravenous 15 mg\/kg amikacin dose provides inadequate pharmacokinetic\u2013pharmacodynamic target attainment at the locally reported minimum inhibitory concentration (MIC) of 2 mg\/L and the European Committee on Antimicrobial Susceptibility Testing clinical breakpoint for Enterobacterales of 8 mg\/L.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>To provide an amikacin dosing strategy with a clinically acceptable probability of target attainment (PTA) for all patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Stochastic simulations were performed using a two-compartment population pharmacokinetics model of amikacin (NONMEM 7.5). PTA was evaluated for various dosing strategies across a range of virtual patients' body weight, body mass index, serum total protein, serum sodium, fluid balance, and estimated glomerular filtration rate according to the Chronic Kidney Disease Epidemiology Collaboration equation (eGFR<jats:sub>CKD-EPI<\/jats:sub>), at the locally reported MIC of 2 mg\/L and the clinical breakpoint of 8 mg\/L. The pharmacokinetic\u2013pharmacodynamic targets were a 24-hour area under the concentration\u2013time curve (AUC<jats:sub>24h<\/jats:sub>)\/MIC of \u226580 and a 24-hour postdose concentration (C<jats:sub>24h<\/jats:sub>) of &lt; 3 mg\/L for efficacy and safety, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The PTA for the clinical breakpoint of 8 mg\/L was &lt;90% with standard 15 mg\/kg dosing, across all patient characteristics. A flat 1500-mg dose achieved \u226590% PTA for the entire population at a MIC of 2 mg\/L. However, at the clinical breakpoint of 8 mg\/L, a flat 3500-mg dose provided \u226590% PTA only when the eGFR<jats:sub>CKD-EPI<\/jats:sub> was &lt;96 mL\/min\/1.73 m<jats:sup>2<\/jats:sup>. The C<jats:sub>24h<\/jats:sub> was similar for 1500 mg and 15 mg\/kg dosing, whereas 3500 mg resulted in a higher C<jats:sub>24h<\/jats:sub>.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>A flat dose is recommended over weight-based dosing. However, selecting a 1500-mg or 3500-mg dose may compromise either efficacy (MIC 2 mg\/L) or safety (clinical breakpoint 8 mg\/L), posing a dilemma. Clinical validation is warranted.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001279","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T13:00:10Z","timestamp":1733230810000},"page":"353-362","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Dose Optimization of Amikacin in the Emergency Department: A Population Pharmacokinetics Simulation Study"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1818-1949","authenticated-orcid":false,"given":"Nada","family":"Dia","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, KU Leuven;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"De Winter","sequence":"additional","affiliation":[{"name":"Pharmacy Department, University Hospitals Leuven;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Gijsen","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, KU Leuven;"},{"name":"Pharmacy Department, University Hospitals Leuven;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Desmet","sequence":"additional","affiliation":[{"name":"University Hospitals Leuven, National Reference Centre for Streptococcus Pneumonia;"},{"name":"Department of Microbiology, Immunology and Transplantation, KU Leuven; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vanbrabant","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, KU Leuven; and"},{"name":"Department of General Internal Medicine, University Hospitals Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willy","family":"Peetermans","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, KU Leuven; and"},{"name":"Department of General Internal Medicine, University Hospitals Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Spriet","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, KU Leuven;"},{"name":"Pharmacy Department, University Hospitals Leuven;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0785-2930","authenticated-orcid":false,"given":"Erwin","family":"Dreesen","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, KU Leuven;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"key":"R1-20250509","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1056\/NEJMp1707170","article-title":"Recognizing sepsis as a global health priority\u2014a WHO resolution","volume":"377","author":"Reinhart","year":"2017","journal-title":"New Engl J Med."},{"key":"R2-20250509","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990\u20132017: analysis for the Global Burden of Disease Study","volume":"395","author":"Rudd","year":"2020","journal-title":"Lancet"},{"key":"R3-20250509","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/CCM.0000000000005357","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"49","author":"Evans","year":"2021","journal-title":"Crit Care Med."},{"key":"R4-20250509","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1086\/520991","article-title":"Back to the future: using aminoglycosides again and how to dose them optimally","volume":"45","author":"Eliopoulos","year":"2007","journal-title":"Clin Infect Dis."},{"key":"R5-20250509","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/20786190.2014.1002220","article-title":"Aminoglycoside-induced hearing deficits\u2014a review of cochlear ototoxicity","volume":"57","author":"Petersen","year":"2015","journal-title":"S Afr Fam Pract."},{"key":"R6-20250509","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jiac.2020.09.033","article-title":"A meta-analysis of the target trough concentration of gentamicin and amikacin for reducing the risk of nephrotoxicity","volume":"27","author":"Yamada","year":"2021","journal-title":"J Infect Chemother."},{"key":"R7-20250509","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1097\/CCM.0b013e3181cc4824","article-title":"Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department","volume":"38","author":"Gaieski","year":"2010","journal-title":"Crit Care Med."},{"key":"R8-20250509","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s13318-021-00698-w","article-title":"Quantification and explanation of the variability of first-dose amikacin concentrations in critically ill patients admitted to the emergency department: a population pharmacokinetic analysis","volume":"46","author":"De Winter","year":"2021","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"R9-20250509","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/phar.2193","article-title":"Reappraisal of contemporary pharmacokinetic and pharmacodynamic principles for informing aminoglycoside dosing","volume":"38","author":"Bland","year":"2018","journal-title":"Pharmacother J Hum Pharmacol Drug Ther."},{"key":"R12-20250509","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijantimicag.2017.11.009","article-title":"Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: a randomised controlled trial","volume":"51","author":"De Winter","year":"2018","journal-title":"Int J Antimicrob Agents."},{"key":"R13-20250509","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s10928-006-9033-1","article-title":"Simulation of correlated continuous and categorical variables using a single multivariate distribution","volume":"33","author":"Tannenbaum","year":"2006","journal-title":"J Pharmacokinet Phar."},{"key":"R14-20250509","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1007\/s11095-015-1699-x","article-title":"Generating virtual patients by multivariate and discrete re-sampling techniques","volume":"32","author":"Teutonico","year":"2015","journal-title":"Pharm Res"},{"key":"R15-20250509","doi-asserted-by":"crossref","first-page":"6354","DOI":"10.1136\/bmj.e6354","article-title":"Monitoring aminoglycoside level","volume":"345","author":"Banerjee","year":"2012","journal-title":"Br Med J."},{"key":"R16-20250509","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/MAT.0000000000000689","article-title":"Pharmacokinetics of amikacin in critical care patients on extracorporeal device","volume":"64","author":"Ruiz-Ramos","year":"2018","journal-title":"ASAIO J."},{"key":"R19-20250509","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J Open Source Softw."},{"key":"R21-20250509","doi-asserted-by":"crossref","first-page":"e933","DOI":"10.1128\/AAC.00993-19","article-title":"Amikacin initial dose in critically ill patients: a nonparametric approach to optimize A priori pharmacokinetic\/pharmacodynamic target attainments in individual patients","volume":"63","author":"Boidin","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"R22-20250509","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1128\/AAC.40.7.1682","article-title":"Population pharmacokinetics of amikacin in critically ill patients","volume":"40","author":"Bressolle","year":"1996","journal-title":"Antimicrob Agents Chemother."},{"key":"R23-20250509","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF03190009","article-title":"A population approach to the forecasting of amikacin plasma and urinary levels using a prescribed dosage regimen","volume":"24","author":"Joubert","year":"1999","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"R24-20250509","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/FTD.0b013e3181f675c2","article-title":"Population pharmacokinetic modeling and optimal sampling strategy for bayesian estimation of amikacin exposure in critically ill septic patients","volume":"32","author":"Delattre","year":"2010","journal-title":"Ther Drug Monit."},{"key":"R25-20250509","first-page":"1","article-title":"Amikacin population pharmacokinetics in critically ill Kuwaiti patients","volume":"2013","author":"Matar","year":"2013","journal-title":"Biomed Res Int."},{"key":"R26-20250509","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00228-014-1766-y","article-title":"Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia","volume":"71","author":"Burdet","year":"2015","journal-title":"Eur J Clin Pharmacol."},{"key":"R27-20250509","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40268-016-0165-5","article-title":"Evaluation of amikacin pharmacokinetics and pharmacodynamics for optimal initial dosing regimen","volume":"17","author":"Kato","year":"2017","journal-title":"Drugs RD."},{"key":"R28-20250509","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s40262-018-0641-x","article-title":"Clinical pharmacokinetics of amikacin in pediatric patients: a comprehensive review of population pharmacokinetic analyses","volume":"57","author":"Illamola","year":"2018","journal-title":"Clin Pharmacokinet."},{"key":"R29-20250509","doi-asserted-by":"crossref","first-page":"e1788","DOI":"10.1128\/AAC.02178-19","article-title":"Population pharmacokinetics of amikacin administered once daily in patients with different renal functions","volume":"64","author":"Ar\u00e9chiga-Alvarado","year":"2020","journal-title":"Antimicrob Agents Chemother."},{"key":"R30-20250509","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3390\/antibiotics12010123","article-title":"Development of a predictive dosing nomogram to achieve PK\/pd targets of amikacin initial dose in critically ill patients: a non-parametric approach","volume":"12","author":"Coste","year":"2023","journal-title":"Antibiotics."},{"key":"R31-20250509","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1472-8206.1995.tb00266.x","article-title":"Population pharmacokinetics of amikacin in intensive care unit patients studied by NPEM algorithm","volume":"9","author":"Debord","year":"1995","journal-title":"Fund Clin Pharmacol."},{"key":"R32-20250509","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1007\/s00134-014-3276-x","article-title":"Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg\/kg total body weight regimen","volume":"40","author":"de Montmollin","year":"2014","journal-title":"Intens Care Med."},{"key":"R33-20250509","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/cc8945","article-title":"Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock","volume":"14","author":"Taccone","year":"2010","journal-title":"Crit Care."},{"key":"R34-20250509","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijantimicag.2011.03.022","article-title":"Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity","volume":"38","author":"G\u00e1lvez","year":"2011","journal-title":"Int J Antimicrob Agents."},{"key":"R35-20250509","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000440867","article-title":"Acute kidney injury and renal recovery with the use of aminoglycosides: a large retrospective study","volume":"131","author":"Paquette","year":"2015","journal-title":"Nephron."},{"key":"R36-20250509","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/antibiotics12020373","article-title":"Therapeutic drug monitoring of amikacin in neutropenic oncology patients","volume":"12","author":"Aquino","year":"2023","journal-title":"Antibiotics."},{"key":"R37-20250509","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1086\/420742","article-title":"Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases","volume":"38","author":"Peloquin","year":"2004","journal-title":"Clin Infect Dis."},{"key":"R38-20250509","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/clinids\/24.5.786","article-title":"A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides","volume":"24","author":"Bailey","year":"1997","journal-title":"Clin Infect Dis."},{"key":"R39-20250509","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/0002-9343(90)90099-Y","article-title":"Once-daily dosing regimen for aminoglycoside plus, lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone","volume":"89","author":"Ter braak","year":"1990","journal-title":"Am J Med."},{"key":"R40-20250509","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1128\/AAC.43.7.1549","article-title":"Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity","volume":"43","author":"Rybak","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"R41-20250509","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/infdis\/167.1.173","article-title":"Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring","volume":"167","author":"Bertino","year":"1993","journal-title":"J Infect Dis."},{"key":"R42-20250509","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1128\/AAC.39.3.650","article-title":"Experience with a once-daily aminoglycoside program administered to 2,184 adult patients","volume":"39","author":"Nicolau","year":"1995","journal-title":"Antimicrob Agents Chemother."},{"key":"R43-20250509","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2147\/IDR.S150839","article-title":"High-dose amikacin for achieving serum target levels in critically ill elderly patients","volume":"11","author":"Sadeghi","year":"2018","journal-title":"Infect Drug Resist."},{"key":"R44-20250509","doi-asserted-by":"crossref","first-page":"e1655","DOI":"10.1128\/AAC.02165-18","article-title":"A systematic review of single-dose aminoglycoside therapy for urinary tract infection: is it time to resurrect an old strategy?","volume":"63","author":"Goodlet","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"R45-20250509","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3109\/00365548.2012.747694","article-title":"Rational use of aminoglycosides\u2014review and recommendations by the Swedish reference group for antibiotics (SRGA)","volume":"45","author":"Hanberger","year":"2013","journal-title":"Scand J Infect Dis."},{"key":"R47-20250509","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ejhpharm-2022-003421","article-title":"Systematic review of high-dose amikacin regimens for the treatment of Gram-negative infections based on EUCAST dosing recommendations","volume":"30","author":"Frost","year":"2023","journal-title":"Eur J Hosp Pharm."},{"key":"R49-20250509","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/jac\/dky195","article-title":"MIC-based dose adjustment: facts and fables","volume":"73","author":"Mouton","year":"2018","journal-title":"J Antimicrob Chemoth."},{"key":"R51-20250509","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ccc.2010.11.006","article-title":"Optimizing aminoglycoside use","volume":"27","author":"Craig","year":"2011","journal-title":"Crit Care Clin."},{"key":"R52-20250509","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/ofid\/ofac626","article-title":"Optimizing clinical outcomes through rational dosing strategies: roles of pharmacokinetic\/pharmacodynamic modeling tools","volume":"9","author":"Chua","year":"2022","journal-title":"Open Forum Infect Dis."},{"key":"R53-20250509","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1093\/jac\/dkw250","article-title":"Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review","volume":"71","author":"Jenkins","year":"2016","journal-title":"J Antimicrob Chemoth."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T12:00:41Z","timestamp":1746792041000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001279","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,3]]},"assertion":[{"value":"2024-02-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}